Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression.
Saved in:
| Title: | Rova-T enhances the anti-tumor activity of anti-PD1 in a murine model of small cell lung cancer with endogenous Dll3 expression. |
|---|---|
| Authors: | Vitorino P; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA. Electronic address: philip.vitorino@abbvie.com., Chuang CH; AMGEN, 1120 Veterans Boulevard, South San Francisco, CA 94087, USA., Iannello A; Actym Therapeutics, 626 Bancroft Way Suite A, Berkeley, CA 94710, USA., Zhao X; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Anderson W; Notable Labs, 320 Hatch Drive, Foster City, CA 94404, USA., Ferrando R; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Zhang Z; AbbVie LLC, 450 E Jamie Court, South San Francisco, CA 94080, USA., Madhavan S; UNITY Biotechnology, 285 E Grand Ave, South San Francisco, CA 94080, USA., Karsunky H; Deep Valley Labs, 3031 Tisch Way 605, San Jose, CA 95128, USA., Saunders LR; Everest Detection, 409 Illinois Street, San Francisco, CA 94158, USA. |
| Source: | Translational oncology [Transl Oncol] 2021 Jan; Vol. 14 (1), pp. 100883. Date of Electronic Publication: 2020 Oct 15. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Neoplasia Press Country of Publication: United States NLM ID: 101472619 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1936-5233 (Print) Linking ISSN: 19365233 NLM ISO Abbreviation: Transl Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
